Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352 on ClinicalTrials.gov · last registry update 2025-02-18

Finished 31 March 2023, after enrolling 60 people. Primary outcome, as filed: Mean Change in HbA1C ≤ 7.5%. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: The Cleveland Clinic
Sponsor type: Other
Enrollment: 60
Started: 2021-01-18
Primary completion: 2023-03-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change in HbA1C ≤ 7.5%

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.